Chemomab Therapeutics ADR Aktie

—Achieves FDA Alignment on CMC and Non-Clinical Toxicology Regulatory Path for Nebokitug in PSC— —Preparations for the Nebokitug PSC Phase 3 Clinical Trial Advance as Discussions with Potential Strategic Partners Continue— TEL AVIV, Israel, June 11, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd., (Nasdaq: CMMB), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today reported that it has obtained confirmation from the FDA on two significant development milestones as the company continues to finalize the nebokitug Phase 3 program.» Mehr auf globenewswire.com

—New Patent s Covering Use of Nebokitug for the Treatment of Liver Diseases including Primary Sclerosing Cholangitis Issued in China and Russia Providing Coverage Up T o 2041 — —Further Ex pands Protections Provided by Nebokitug 's Composition of Matter and Methods and Use Patents Issued in the U.S., Europe, Japan and A dditional Key Territories— TEL AVIV, Israel, June 03, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics, Ltd., (Nasdaq: CMMB), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that its lead product nebokitug (formerly CM-101) has been awarded new patent protections in China and Russia.» Mehr auf globenewswire.com

— Reported Positive 48-Week Data from SPRING Trial — Nebokitug Treatment in PSC P atients with M oderate/ A dvanced D isease R esulted in C ontinued I mprovements across K ey B iomarkers of Li ver I njury, I nflammation and Fi brosis — — Align ed with FDA on Pathway to Potential Regulatory Approval for the Treatment of PSC with a Single, Clinical-Events-Driven Clinical Trial— — Th e se Major Milestones Support the Advancement of Nebokitug to Phase 3 and Position It to Potentially Become the First FDA-Approved Treatment for PSC — — Cash Runway E xtended to the S econd Quarter of 2026 — — Company Advancing Multiple Partnering Options for Executing the Nebokitug Program — TEL AVIV, Israel, May 15, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd.(Nasdaq:CMMB), (Chemomab), a clinical-stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced financial and operating results for the first quarter ended March 31, 2025, and provided a corporate update.» Mehr auf globenewswire.com